Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
Bluebird Bio (BLUE) Stock Price & Analysis
2,546 Followers
BLUE Stock Chart & Stats
Day’s Range$1.02 - $1.16
52-Week Range― - ―
Previous Close$1.12
Volume5.87M
Average Volume (3M)N/A
Market Cap
$198.52M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
Aug 06, 2024EPS EstimateN/A
Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.67Price Target Upside256.31% Upside
Rating ConsensusHold
Number of Analyst Covering11
Bluebird Bio News
PremiumStock Analysis & Ideas
CRISPR Therapeutics Stock (NASDAQ:CRSP) Pushes Lower, But Fundamentals Are Intact
PremiumCompany Announcements
Bluebird Bio Faces Nasdaq Compliance Challenge and Delays
PremiumStock Analysis & Ideas
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game?Bulls Say, Bears Say
Bulls Say
Financial PerformanceZynteglo revenue gains momentum, indicating a growing market acceptance and increased sales which could lead to higher financial returns for investors.
Market ExpansionBluebird has expanded its reach to 64 qualified treatment centers, potentially increasing patient access and boosting demand for its innovative treatments.
Strategic PartnershipsBLUE has signed its first Medicaid outcomes-based agreement and is engaging with over 15 Medicaid agencies, potentially widening patient access and improving market penetration for its products.
Bears Say
Financial PerformanceProduct revenue for the first quarter was below both estimates and consensus, indicating a potential shortfall in the company's financial health.
Investor ConfidenceThe restatement of 2022/23 financials for treatment of leases is a blow to investor confidence for BLUE.
Market PerformanceLaunch in the SCD market appears to lack initial momentum, raising concerns about meeting patient start guidance.
---
Ownership Overview
4.95% Insiders
11.40% Mutual Funds
11.25% Other Institutional Investors
72.40% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BLUE FAQ
What was bluebird bio’s price range in the past 12 months?
Currently, no data Available
What is bluebird bio’s market cap?
Currently, no data Available
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is Aug 06, 2024 which is in 88 days.
How were bluebird bio’s earnings last quarter?
bluebird bio released its earnings results on May 09, 2024. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.45 by $0.07.
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $8.88 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does bluebird bio have?
Currently, no data Available
What happened to bluebird bio’s price movement after its last earnings report?
bluebird bio reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.45. Following the earnings report the stock price went up 15.464%.
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Farallon Capital Management, L.L.C.. It holds bluebird bio’s shares valued at 3M.
---
Bluebird Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.67 (256.31% Upside)
$3.67 (256.31% Upside)
Blogger Sentiment
Bullish
BLUE Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 925.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $26.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
BLUE Earnings Call
Q1 2024
0:00 / 0:00
---
BLUE Stock 12 Month Forecast
Average Price Target
$3.67
▲(256.31% Upside)
Technical Analysis
Best Analysts Covering BLUE
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+46.99%
reiterated a buy rating 2 months ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +46.99% per trade.
---